Lakeway, TX -- (SBWIRE) -- 02/25/2013 -- Bestdamnpennystocks, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-
Goldman Sachs continues to view Sell-rated Walter Energy (WLT -2.3%) as overvalued even after Q4 results sent shares tumbling 11%; WLT has missed consensus EBITDA estimates in six of the past eight quarters. The firm needs to see better execution in Canada, sharply higher met coal prices, and improved financial flexibility via restructuring or finding a partner to fund its growth projects.
Is WLT after A Solid Pop Up? Find Out Here
SAP (SAP -0.1%) strengthens its supply-chain management (SCM) hand by acquiring SmartOps, a developer of software that uses algorithms to optimize inventory, predict demand, and manage distribution networks. SAP notes SmartOps complements its existing SCM apps, and will help it develop real-time SCM analytics software powered by its Hana in-memory database. Separately, SAP is rolling out a mobile document access/management product; the company's Sybase unit is already a top developer of enterprise mobile apps.
Will SAP Continue To Trend Higher After The Recent Gain? Find Out Here
Cummins (CMI +0.5%) bucks a weak tape after Goldman Sachs ups the shares to Conviction Buy with a price target of $144. The price target represents a 30% upside from current levels, as Goldman says it's expecting a strong new product cycle in machinery, with contract awards in the coming months that could exceed $1B. The firm adds that CMI's core global truck markets are also in the early stages of recovery as production rises off trough 1Q levels.
Is CMI a Buy Opportunity After The Recent Slump? Find Out Here
Medtronic (MDT -0.3%) says the FDA has approved the 34mm and 38mm lengths of its Resolute Integrity drug-eluting stent for treating patients with diabetes. The new sizes will enable the treatment of long coronary lesions, which are generally considered to span more than 27mm, and are uniquely indicated for treating coronary artery disease in patients with diabetes, who commonly present with long lesions.
Is MDT Still a Buy After The Recent momentum? Find Out Here
Best Damn Penny Stocks’ team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.
The assembled information disseminated by Bestdamnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Bestdamnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in Bestdamnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)